Pulsenmore

Company Overview

Snapshot

Founded in October 2014 by Elazar Sonnenschein, Pulsenmore operates with 51–200 employees. The company has raised a total of $110.8M across 5 funding rounds from 6 investors. In January 2026, Pulsenmore announced its shares would commence trading on Nasdaq, expanding its FDA-authorized home prenatal ultrasound devices in the U.S.

Business overview

Pulsenmore develops a reliable, universally accessible home ultrasound device designed for remote care. Its core technology allows patients to perform self-scans by connecting their smartphone to a handheld ultrasound cradle, with scans automatically sent for remote clinical assessment by healthcare providers. The company's at-home prenatal ultrasound system for fetal monitoring empowers women to proactively manage their pregnancies. Pulsenmore operates within the Health Tech & Life Sciences sector, specifically focusing on Medical Devices, Digital Healthcare, and Patient Remote Monitoring, serving markets in Israel, the United States, and Europe.

Strategic signal

Pulsenmore is poised for significant expansion in the U.S. market following its FDA De Novo Marketing Authorization for home-use prenatal ultrasound in November 2025. This regulatory milestone, coupled with its planned Nasdaq listing in January 2026 and initial commercial engagements, signals a strategic pivot towards broader market penetration and increased investor visibility in the critical American healthcare landscape.

Company Intelligence Q&A

What significant regulatory approval did Pulsenmore receive in the U.S.?

In November 2025, Pulsenmore received FDA De Novo Marketing Authorization for its home-use prenatal ultrasound device, marking a new era for prenatal care in the U.S.

What was a key strategic development for Pulsenmore in January 2026?

In January 2026, Pulsenmore announced its shares would commence trading on Nasdaq, coinciding with the expansion of its FDA-authorized home prenatal ultrasound devices in the U.S.

When did Pulsenmore expand its partnership with Clalit Health Services?

In October 2024, Pulsenmore expanded its partnership with Clalit Health Services to deliver 25,000 home ultrasound devices for remote prenatal care.

What new commercial engagement did Pulsenmore announce in February 2026?

In February 2026, Pulsenmore announced its first commercial engagement with a leading U.S.-based medical center, building momentum in the U.S. market after FDA clearance.

What leadership appointment did Pulsenmore make in June 2024?

In June 2024, Pulsenmore appointed Len Farris as.